计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| E121713-100mg |
100mg |
现货 ![]() |
| |
| E121713-250mg |
250mg |
期货 ![]() |
| |
| E121713-500mg |
500mg |
现货 ![]() |
| |
| E121713-1g |
1g |
期货 ![]() |
| |
| E121713-5g |
5g |
现货 ![]() |
|
| 别名 | 依托泊苷 | :4'-去甲基表鬼臼毒素 9-(4,6-O-亚乙基-β-D-吡喃葡萄糖苷) | 4'-去甲基表鬼臼毒素 -(4,6-O-亚乙基-β-D-吡喃葡萄糖苷) | 臼乙叉苷 | 足叶乙甙 |
|---|---|
| 英文别名 | VP-16-213 | 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) | ETOPOSIDE [HSDB] | ETOPOSIDE [IARC] | (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6- |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Etoposide |
| 生化机理 | 依托泊苷是一种抗肿瘤药,能与拓扑异构酶 II 和 DNA 复合物,增强 DNA 的双链和单链裂解,并可逆地抑制复配。在细胞周期的 S 期和 G2 期阻滞细胞周期;诱导正常细胞系和肿瘤细胞系凋亡;抑制肿瘤蛋白 Mdm2 的合成,并诱导过度表达 Mdm2 的肿瘤细胞系凋亡。抗癌剂。 |
| 储存温度 | 避光,-20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | DNA 拓扑异构酶 II 抑制剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
依托泊苷是一种抗肿瘤剂,它与拓扑异构酶Ⅱ及DNA结合成复合物,以增强双链和单链DNA的裂解,并可逆地抑制再连接。在细胞周期S期和G2期阻断细胞周期,在正常和肿瘤细胞系中诱导细胞凋亡,抑制癌蛋白Mdm2的合成,在过渡表达Mdm2的肿瘤细胞系中诱发细胞凋亡。Inhibits DNA synthesis via topoisomerase II inhibition Etoposide (VP-16; VP-16-213) 是一种常用的抗肿瘤化疗剂。Etoposide 抑制拓扑异构酶 II (topoisomerase-II),从而抑制 DNA 复制。Etoposide 诱导细胞周期停滞,凋亡 (apoptosis) 和自噬 (autophagy)。 Etoposide is an antitumor agent that complexes with topoisomerase II and DNA to enhance double-strand and single-strand cleavage of DNA and reversibly inhibit religation. Blocks the cell cycle in in S-phase and G2-phase of the cell cycle; induces apoptosis in normal and tumor cell lines; inhibits synthesis of the oncoprotein Mdm2 and induces apoptosis in tumor lines that overexpress Mdm2. product description: Etoposide is synthesised from podophyllotoxins of plants. |
| 纯度 | ≥98% |
| ALogP | 0.6 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504753550 |
|---|---|
| EC号 | 251-509-1 |
| 分子类型 | 小分子 |
| IIUPAC Name | (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one |
| INCHI | 1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1 |
| InChi Key | VJJPUSNTGOMMGY-MRVIYFEKSA-N |
| Smiles | CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O |
| Isomeric SMILES | C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O |
| 关联CAS | 33419-42-0 |
| 分子量 | 588.56 |
| Reaxy-Rn | 365969 |
| 溶解性 | Soluble in DMSO (30 mg/ml), dimethyl formamide, ethyl ether, chloroform:methanol (1:1), methanol (slightly), acetone (slightly), water (<1 mg/ml) at 25 °C, and ethanol (<1 mg/ml) at 25 °C |
|---|---|
| 敏感性 | 对光线敏感 |
| 比旋光度 | -110.5° (C=0.6,CHCl3) |
| 熔点 | 251°C |
| 分子量 | 588.600 g/mol |
| XLogP3 | 0.600 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 13 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 588.184 Da |
| 单同位素质量Monoisotopic Mass | 588.184 Da |
| 拓扑极表面积Topological Polar Surface Area | 161.000 Ų |
| 重原子数Heavy Atom Count | 42 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 969.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 10 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07, GHS08 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H302: 吞食有害 H340: 可能导致遗传缺陷 H350: 可能导致癌症 H360: 可能损害生育力或未出生的孩子 |
| 预防措施声明 |
P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P330: 漱口 P301+P312: 如误吞咽:如感觉不适,呼叫急救中心/医生。 P308+P313: 如接触到或有疑虑:求医/就诊。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 |
| WGK Germany | 3 |
| RTECS | KC0190000 |
| Merck Index | 3886 |
| 个人防护装备 | Eyeshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 | |
| 分析证书 | E121713 |
¥185.90
| 1. Lammert CR et al.. (2020) AIM2 inflammasome surveillance of DNA damage shapes neurodevelopment.. Nature, 580 (7805): (647-652). [PMID:32350463] |
| 2. Tian R et al.. (2019) CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons.. Neuron, 104 (2): (239-255.e12). [PMID:31422865] |
| 3. Saliou B et al.. (2013) Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide.. Eur J Pharm Sci, 50 (2): (172-80). [PMID:23831519] |
| 4. Sultana S & Bishayi B. (2020) Etoposide-mediated depletion of peripheral blood monocytes post s.aureus infection attenuates septic arthritis by modulating macrophage-derived factors responsible for inflammatory destruction.. Immunol Lett, 220 (51-62). [PMID:32032616] |
| 5. Hijaze N et al.. (2020) Inducing regulated necrosis and shifting macrophage polarization with anti-EMMPRIN antibody (161-pAb) and complement factors.. J Leukoc Biol, [PMID:33205451] |
| 6. Moretti FA et al.. (2021) Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy.. Sci Rep, 11 (23221). [PMID:34853379] |
| 7. Ulrich G et al.. (2018) Phosphorylation of nuclear Tau is modulated by distinct cellular pathways.. Sci Rep, 8 (17702). [PMID:30531974] |
| 8. Sola M et al.. (2020) Tau affects P53 function and cell fate during the DNA damage response.. Commun Biol, 3 (245). [PMID:32427887] |
| 9. Hu Q et al.. (2020) The ARK Assay Is a Sensitive and Versatile Method for the Global Detection of DNA-Protein Crosslinks.. Cell Rep, 30 (4): (1235-1245.e4). [PMID:31995761] |
| 10. Zhuangzhuang Li, Baoyan Ding, Mustafa R. K. Ali, Lizhen Zhao, Xiaoling Zang, Zhihua Lv. (2022) Dual Effect of Tryptamine on Prostate Cancer Cell Growth Regulation: A Pilot Study. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23 (19): (11087). [PMID:36232383] [10.3390/ijms231911087] |
| 11. Ma Xiaojing, Wang Tong, Yu Zequan, Shao Junqian, Chu Jun, Zhu Huixia, Yao Risheng. (2022) Formulation and Physicochemical and Biological Characterization of Etoposide-Loaded Submicron Emulsions with Biosurfactant of Sophorolipids. AAPS PHARMSCITECH, 23 (6): (1-13). [PMID:35773548] [10.1208/s12249-022-02329-2] |
| 12. Wang Xiao, Xu Na, Li Qinglin, Chen Shengqi, Cheng Hui, Yang Mo, Jiang Ting, Chu Jun, Ma Xiaojing, Yin Dengke. (2021) Lactonic sophorolipid–induced apoptosis in human HepG2 cells through the Caspase-3 pathway. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 105 (5): (2033-2042). [PMID:33582833] [10.1007/s00253-020-11045-5] |
| 13. Meifang Cai, Caiping Ding, Xuanyu Cao, Fangfang Wang, Cuiling Zhang, Yuezhong Xian. (2019) Label-free fluorometric assay for cytochrome c in apoptotic cells based on near infrared Ag2S quantum dots. ANALYTICA CHIMICA ACTA, 1056 (153). [PMID:30797456] [10.1016/j.aca.2019.01.005] |
| 14. Jingwei Wang, Zhiheng Guo, Jianxin Xiong, Datong Wu, Shan Li, Yongxin Tao, Yong Qin, Yong Kong. (2019) Facile synthesis of chitosan-grafted beta-cyclodextrin for stimuli-responsive drug delivery. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 125 (941). [PMID:30572042] [10.1016/j.ijbiomac.2018.12.150] |
| 15. Xiaolin Liu, Yongxin Tao, Huihui Mao, Yong Kong, Jian Shen, Linhong Deng, Linsong Yang. (2017) Construction of magnetic-targeted and NIR irradiation-controlled drug delivery platform with Fe3O4@Au@SiO2 nanospheres. CERAMICS INTERNATIONAL, 43 (5061). [10.1016/j.ceramint.2017.01.017] |
| 16. Junling Wang, Ran Wang, Fangrong Zhang, Yajun Yin, Leixia Mei, Fengjuan Song, Mingtao Tao, Wanqing Yue, Wenying Zhong. (2016) Overcoming multidrug resistance by a combination of chemotherapy and photothermal therapy mediated by carbon nanohorns. Journal of Materials Chemistry B, 4 (36): (6043-6051). [PMID:32263493] [10.1039/C6TB01469K] |
| 17. Lian Chen, Hengmin Cui, Jing Fang, Huidan Deng, Ping Kuang, Hongrui Guo, Xun Wang, Ling Zhao. (2016) Glutamine deprivation plus BPTES alters etoposide- and cisplatin-induced apoptosis in triple negative breast cancer cells. Oncotarget, 7 (34): ( 54691–54701). [PMID:27419628] [10.18632/oncotarget.10579] |
| 18. Yadong Tang,Boxin Huang,Yuqin Dong,Wenlong Wang,Xi Zheng,Wei Zhou,Kun Zhang,Zhiyun Du. (2017-06-07) Three-dimensional prostate tumor model based on a hyaluronic acid-alginate hydrogel for evaluation of anti-cancer drug efficacy.. Journal of biomaterials science. Polymer edition, 28 ((14)): (1603-1616). [PMID:28583017] |
| 19. Xiaolan Zhou, Xiaofeng Zhu, Weixu Wang, Jing Wang, Haimei Wen, Yuqi Zhao, Jiayu Zhang, Qiushi Xu, Zhaozhao Zhao, Ting Ni. (2025) Comprehensive Cellular Senescence Evaluation to Aid Targeted Therapies. Research, 8 (2025 Jan;8). [PMID:39822281] [10.34133/research.0576] |